Get the Stockscreener App
0.4805
5.00%
0.0229
Pre-market:
.47
-0.0105
-2.19%
Jasper Therapeutics Inc stock is traded at $0.4805, with a volume of 509.05K.
It is up +5.00% in the last 24 hours and down -43.48% over the past month.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
See More
Previous Close:
$0.4576
Open:
$0.453
24h Volume:
509.05K
Relative Volume:
1.03
Market Cap:
$13.45M
Revenue:
-
Net Income/Loss:
$-55.73M
P/E Ratio:
-0.1489
EPS:
-3.2274
Net Cash Flow:
$-68.87M
1W Performance:
+2.67%
1M Performance:
-43.48%
6M Performance:
-70.70%
1Y Performance:
-91.39%
1-Day Range:
$0.453
$0.5205
1-Week Range:
$0.42
$0.5205
52-Week Range:
$0.42
$7.19
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Name
Jasper Therapeutics Inc
Sector
Industry
Phone
(650) 549-1400
Address
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
0.4805 | 13.45M | 0 | -55.73M | -68.87M | -3.2274 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-26 | Resumed | UBS | Neutral |
| Jan-13-26 | Initiated | Rodman & Renshaw | Buy |
| Jul-08-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-07-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-13-25 | Initiated | UBS | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Sep-09-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-08-24 | Initiated | BTIG Research | Buy |
| Jun-27-24 | Initiated | Stifel | Buy |
| May-06-24 | Initiated | H.C. Wainwright | Buy |
| Apr-03-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-18-24 | Initiated | TD Cowen | Outperform |
| Aug-11-23 | Initiated | CapitalOne | Overweight |
| Feb-28-22 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Credit Suisse | Outperform |
| Oct-21-21 | Initiated | William Blair | Outperform |
| Oct-20-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-13-21 | Initiated | Oppenheimer | Outperform |
View All
Jasper Therapeutics Inc Stock (JSPR) Latest News
Jasper Therapeutics (NASDAQ: JSPR) outlines 2026 virtual meeting, board and pay votes - Stock Titan
Jasper Therapeutics (JSPR) Edges Lower, Testing Key Support Near $0.44Seasonality Effect - newsline.com
Jasper Therapeutics Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
Nasdaq warns Jasper Therapeutics (JSPR) on sub-$1 bid, delisting risk noted - Stock Titan
Jasper Therapeutics (JSPR) Edges Higher Amid Tight Trading RangeAndrews Pitchfork - newsline.com
symbol__ Stock Quote Price and Forecast - CNN
Deal Dispatch: Jasper Therapeutics For Sale, RobinHood Completes $180 Million WonderFi Acquisition, Long John Silver's Franchisee To Liquidate - Dailyhunt
JSPR Q1 2026 Earnings: Massive EPS Beat with -$0.04 vs -$0.4965 Estimate; Stock RisesEarnings Power Value - newsline.com
Deal Dispatch: Jasper Therapeutics For Sale, RobinHood Completes $180 Million WonderFi Acquisition, Long - Benzinga
Bears are losing control over Jasper Therapeutics (JSPR), here's why it's a 'buy' now - MSN
Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now - sharewise.com
Jasper Therapeutics Initiates Review of Strategic Alternatives to Maximize Shareholder Value - marketscreener.com
Jasper Therapeutics Explores Sale, Merger and Other Strategic Alternatives - Moomoo
Jasper Therapeutics Weighs Sale as Cash Dwindles, Drug's Fate Uncertain - BriefGlance
Jasper Therapeutics Initiates Strategic Alternatives Review to Maximize Shareholder Value Amid Mast Cell Disease Therapy Focus 1 - Minichart
Jasper Therapeutics Launches Strategic Alternatives Review Amid Uncertainty - TipRanks
Jasper Therapeutics explores strategic alternatives By Investing.com - Investing.com South Africa
Jasper Therapeutics explores strategic alternatives - Investing.com
Jasper Therapeutics begins strategic review to maximize shareholder value - TradingView
Jasper Therapeutics (NASDAQ: JSPR) weighs sale, merger or wind-down options - Stock Titan
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value - GlobeNewswire
JSPR Q1 2026 Earnings: Surprise EPS Beat Overshadowed by Broader HeadwindsAnnual Financial Report - The Legal Advocate
JSPR Q1 2026 Earnings: Narrowed Loss Surpasses Estimates, Stock Slides Despite ProgressProduct Revenue Analysis - newsline.com
Jasper Therapeutics (JSPR) Hovers Near Support as Biotech Sentiment Remains CautiousWave Equality - The Legal Advocate
Jasper Therapeutics (JSPR) Edges Higher: Small-Cap Biotech Tests Resistance at $0.95ETF Flow - The Legal Advocate
Jasper Therapeutics (JSPR) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock Higher - The Legal Advocate
Jasper Therapeutics Announces Board Resignation and Committee Change - TipRanks
Christian Nolet resigns from Jasper Therapeutics board; Svetlana Lucas joins Audit Committee - TradingView
Jasper Therapeutics (NASDAQ: JSPR) reports director exit and audit change - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market SessionGeovax Labs (NASDAQ:GOVX), Jasper Therapeu - Benzinga
Jasper Therapeutics, Inc.Class A Common Stock (NQ: JSPR - The Chronicle-Journal
Jasper Therapeutics stock maintains outperform rating at Citizens By Investing.com - Investing.com Canada
JSPR Downgraded by TD Cowen -- Rating Changed to Hold - GuruFocus
RBC Capital Maintains Jasper Therapeutics(JSPR.US) With Hold Rating, Cuts Target Price to $3 - Moomoo
JSPR Maintained by RBC Capital -- Price Target Lowered to $3.00 - GuruFocus
RBC Cuts Price Target on Jasper Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk - Moomoo
TD Cowen Downgrades Jasper Therapeutics(JSPR.US) to Hold Rating - Moomoo
TD Cowen downgrades Jasper Therapeutics stock rating to Hold By Investing.com - Investing.com Canada
Jasper Therapeutics, Inc. Stock 12‑Month Price Target Cut to $9.08, Implies 847% Upside - TradingView
Jasper Therapeutics shares rise 5% on clinical updates despite Q4 loss - MSN
Jasper Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
[10-Q] Jasper Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Jasper drug sees 67% complete response in CSU trial update - Stock Titan
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Jasper Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Jasper Therapeutics (NASDAQ: JSPR) cuts Q1 2026 loss but flags funding risk - Stock Titan
Jasper Therapeutics (JSPR) price target decreased by 13.33% to 7.73 - MSN
Morgan Stanley units report sub‑5% stakes in Jasper Therapeutics (JSPR) - Stock Titan
TradingKey - TradingKey
Jasper Therapeutics Inc Stock (JSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):